Kelonia Therapeutics is dedicated to advancing genetic medicine through its innovative iGPS® technology, which is designed to deliver genetic material specifically to targeted tissues. This platform builds on extensive research and development, ensuring that the therapeutic payload reaches the intended site efficiently, thereby enhancing the effectiveness of genetic treatments. The focus on precision delivery is crucial for maximizing therapeutic outcomes while minimizing potential side effects, aligning with the company's commitment to patient-centered care.

In addition to its iGPS® technology, Kelonia Therapeutics emphasizes a holistic approach to genetic medicine, integrating scientific advancements with a strong focus on patient needs. The company is actively engaged in the development of next-generation therapies, including cell therapies, which are poised to revolutionize treatment options for various conditions. By prioritizing both scientific innovation and a human-first culture, Kelonia aims to make significant strides in the field of genetic medicine, ultimately delivering tailored solutions for every patient.

United States

Kelonia is pioneering a new wave of genetic medicines using its next generation gene delivery platform. The company’s simple and elegant cutting-edge in vivo gene delivery technology uses a few potent lentiviral vector-like particles to precisely and efficiently deliver in vivo genetic cargo to the desired target tissue, and only that tissue, every time. With an initial focus on developing transformational therapies for solid tumors and hematologic cancers, Kelonia is building a pipeline of genetic medicines for a wide range of diseases, with the bold goal of bringing genetic medicines to every patient in need.

Kelonia Therapeutics

Company Details